Figure 2
Figure 2. Secretion of BZLF1 products or gp350 by EBV-positive B95-8 cells. (A) Detection of BZLF1- and gp350-SCs by ELISpot assays in wells seeded with 102 to 104 EBV-positive B95-8 cells. (B) Enumeration of BZLF1- and gp350-SCs when cells were treated or not with cycloheximide. The ends of the boxes define the 25th and 75th percentiles, with a line at the median; error bars represent the 10th and 90th percentiles.

Secretion of BZLF1 products or gp350 by EBV-positive B95-8 cells. (A) Detection of BZLF1- and gp350-SCs by ELISpot assays in wells seeded with 102 to 104 EBV-positive B95-8 cells. (B) Enumeration of BZLF1- and gp350-SCs when cells were treated or not with cycloheximide. The ends of the boxes define the 25th and 75th percentiles, with a line at the median; error bars represent the 10th and 90th percentiles.

Close Modal

or Create an Account

Close Modal
Close Modal